Alzamend Neuro Inc (ALZN) Stock Price, Quote & News

Company Profile

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-pe...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 722 6333

Website: www.alzamend.com

Address:

3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, United States

Vikingsstrade Oct. 3 at 7:41 PM

Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve! $STI $ALZN $XHG $HIND

0 · Reply

MoonCowBoy Oct. 3 at 12:53 AM

$ALZN $XHG $HIND $GDHG

0 · Reply

MexaTraders Oct. 2 at 8:19 PM

Ticker ASTC is starting to move. 6.40$ break could send ASTC into a potential HALT-up or squeeze. It is breaking out and starting its 300% run now! Can we see a massive run of ASTC into close? Micro float Squeezer is making a move! $JAGX $HCTI $ALZN $BBAI ::

0 · Reply

1Spartantrade1 Oct. 2 at 6:43 PM

Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $MLEC $CDIO $STI $ALZN 🚀

0 · Reply

S2K_TP Oct. 2 at 3:53 PM

$ALZN still here 🚨🎢

0 · Reply

vzlano25 Oct. 2 at 12:08 PM

$GPUS $ALZN .. same BS.. stay away from Milton Charles "Todd" Ault III…

2 · Reply

ExecutiveEdge Oct. 2 at 3:24 AM

Watch IVDA Imagine a stock that trades under $1 today but has the tech, demand, and contracts to be $50 tomorrow. IVDA News dropped today that validates its platform and roadmap. Tiny float, big tech, and sector tailwinds = the perfect setup for a long-term run. $SGH $HAPP $ALZN $GMBL $EJH

0 · Reply

hiwatt Oct. 1 at 2:19 AM

$ALZN And the saga continues. On 5-12, the day his race buddy files a $8M lawsuit, Todd files proposal to sell 516,090 shares. Since then he has sold 521,287, so I wonder if he's about tapped out?https://ir.alzamend.com/sec-filings/all-sec-filings/content/0001214659-25-014420/0001214659-25-014420.pdf

1 · Reply

hiwatt Sep. 30 at 9:22 PM

$ALZN Anybody notice a pattern? Everyday Todd Ault sells his insider shares, it drops to $2.33 and and the buying starts. Six days in a row with $2.33 bottom.

0 · Reply

TradingRunners Sep. 30 at 8:45 PM

Wow what is happening to MTEX right now!? Seems like ALL volume and momentum are shifting into MTEX!! Could it be the next crazy runner of the day?? Bulls should keep it on watch - MTEX is breaking out! Also watching: $JAGX $HCTI $ALZN $BBAI c

1 · Reply

Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Jul 23, 2025, 8:00 AM EDT - 2 months ago

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

Jun 16, 2025, 8:00 AM EDT - 3 months ago

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

May 29, 2025, 8:00 AM EDT - 4 months ago

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 19, 2025, 8:00 AM EDT - 4 months ago

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 13, 2025, 8:00 AM EDT - 5 months ago

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 8, 2025, 8:00 AM EDT - 5 months ago

Alzamend Neuro Announces Reverse Stock Split

May 7, 2025, 8:00 AM EDT - 5 months ago

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

Mar 25, 2025, 8:00 AM EDT - 6 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital

Mar 18, 2025, 8:00 AM EDT - 7 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

Mar 11, 2025, 8:00 AM EDT - 7 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Mar 4, 2025, 8:10 AM EST - 7 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

Feb 25, 2025, 8:00 AM EST - 7 months ago

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

Aug 19, 2024, 9:41 AM EDT - 1 year ago

Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

ABBV

May 7, 2024, 8:00 AM EDT - 1 year ago

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program

Apr 18, 2023, 8:00 AM EDT - 2 years ago

Altasciences Completes Clinical Portion of Alzamend Neuro's Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer's

Apr 4, 2023, 6:30 AM EDT - 2 years ago

Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

Nov 28, 2022, 6:30 AM EST - 3 years ago

BitNile Holdings Contemplates Exchange Offer to Acquire Shares of Its Common Stock

Nov 22, 2022, 8:05 AM EST - 3 years ago

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.

Nov 21, 2022, 7:27 PM EST - 3 years ago

BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period

Nov 1, 2022, 6:30 AM EDT - 3 years ago

BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer's Disease

Sep 22, 2022, 8:00 AM EDT - 3 years ago

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Dec 17, 2021, 11:59 PM EST - 4 years ago

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Dec 17, 2021, 9:54 AM EST - 4 years ago

Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate

Sep 30, 2021, 1:45 PM EDT - 4 years ago

See Why Alzamend Neuro Stock Is Rallying On Thursday

Sep 30, 2021, 11:54 AM EDT - 4 years ago

Why Alzamend Neuro Shares Are Surging Higher Today

Sep 30, 2021, 10:11 AM EDT - 4 years ago

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients' Immunological System to Combat Alzheimer's Disease

Sep 13, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease

Aug 4, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Pursuant to the Securities Purchase Agreement with Digital Power Lending

Jul 30, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient's Immunological System to Combat Alzheimer's

Jul 28, 2021, 3:07 PM EDT - 4 years ago

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Disease

Jul 23, 2021, 7:20 AM EDT - 4 years ago

Alzamend Neuro Stock Shoots Higher As Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models

Jul 23, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer's Disease

Jul 12, 2021, 6:00 AM EDT - 4 years ago

Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today

Jul 1, 2021, 11:23 AM EDT - 4 years ago

Alzamend Neuro Submits IND Application For Alzheimer's-Related Dementia Candidate

Jul 1, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer's Disease

Jun 17, 2021, 4:30 PM EDT - 4 years ago

Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million

Jun 16, 2021, 6:30 AM EDT - 4 years ago

Ault Global Holdings Announces Alzamend Neuro Pricing of Initial Public Offering

Jun 14, 2021, 5:49 PM EDT - 4 years ago

Alzamend Neuro Announces Pricing of Initial Public Offering

Vikingsstrade Oct. 3 at 7:41 PM

0 · Reply

MoonCowBoy Oct. 3 at 12:53 AM

$ALZN $XHG $HIND $GDHG

0 · Reply

MexaTraders Oct. 2 at 8:19 PM

0 · Reply

1Spartantrade1 Oct. 2 at 6:43 PM

0 · Reply

S2K_TP Oct. 2 at 3:53 PM

$ALZN still here 🚨🎢

0 · Reply

vzlano25 Oct. 2 at 12:08 PM

$GPUS $ALZN .. same BS.. stay away from Milton Charles "Todd" Ault III…

2 · Reply

ExecutiveEdge Oct. 2 at 3:24 AM

0 · Reply

hiwatt Oct. 1 at 2:19 AM

1 · Reply

hiwatt Sep. 30 at 9:22 PM

$ALZN Anybody notice a pattern? Everyday Todd Ault sells his insider shares, it drops to $2.33 and and the buying starts. Six days in a row with $2.33 bottom.

0 · Reply

TradingRunners Sep. 30 at 8:45 PM

1 · Reply

NVDAMillionaire Sep. 29 at 9:26 PM

$ALZN Excellent article that nails exactly where ALZN stands right now. So if you want to update your ALZN knowledge or get acquainted with ALZN, this is a must read. https://beyondspx.com/quote/ALZN/analysis/alzamend-neuro-unlocking-brain-health-with-novel-therapies-nasdaq-alzn

0 · Reply

hiwatt Sep. 29 at 7:00 PM

$ALZN Previously we have shown that a novel ionic cocrystal of lithium containing lithium salicylate and proline (LISPRO) is superior to lithium carbonate (LC) and lithium salicylate (LS) in reducing AD pathology in an AD mouse model. The current study was designed to compare the therapeutic effects of LISPRO, LC and LS on cognitive and psychiatric impairments in female AD mice (APPSWE/PS1dE9). Overall, low-dose LISPRO, LC, and LS prevented spatial cognitive decline and depression but LISPRO was superior in reducing associative-memory decline and irritability in comparison with LC and LS.

0 · Reply

hiwatt Sep. 29 at 6:59 PM

$ALZN What I got out of the Katie C interview with Dr Yanker is lithium oritate shows promise with ALZ, but at no point did he suggest it would be just effective with BP, MDD, or PTSD, since it only1/1000 the dose given those BP patients now. Since AL001 is neither lithium carbonate or lithuim orotate, but instead a ionic cocrystal made of lithium, salicylate, and L- proline, could it be the one size shoe that fits all? The test they are doing now does not look at orotate, only carbonate and AL001, but it may give the answers needed to move forward with BP, (Q4 2025) then MDD, and PTSD (Q1 2026), phase 2 studies. and the ALZ (Q2 2026). Let's hope for good numbers, get a bump in stock price so they can do an offering and raise funds to kick the can down the road. Below are results comparing AL001 with other forms of lithium.---

0 · Reply

Noname66 Sep. 29 at 3:43 PM

$ALZN In 2.38 and waiting till next news. I hope.

0 · Reply

KeriKocon133 Sep. 28 at 6:12 PM

Watch drone stocks and IVDA, this one has all of the igredients to yeild big gains from this bottom.. Most AI tickers are hype. IVDA actually has infrastructure, IP, and deployment. They’re building real drone-based threat prevention systems and they’re priced like a dead shell. This won’t stay undiscovered much longer...... $DRCT $ALZN $RCEL $IVDN $AMST

0 · Reply

hiwatt Sep. 28 at 12:46 PM

$ALZN Katie Couric just released a 50 minute interview with Harvard's Bruce Yanker on lithium in the brain. https://youtu.be/fl-X2FyfGcE?si=Jw7r6zIa2ucBrAq8

0 · Reply

hiwatt Sep. 25 at 6:50 PM

$ALZN Isn't it funny, the day Todd Ault started insider selling 5-12-2025, this was the headline, coincidence or not,Hmmm?? May 12, 2025 — The complaint outlines the breach of agreements by Mr. Ault and VForward, resulting in damages of $8,400,000 to Ed Carpenter Racing

1 · Reply

SimSimBola Sep. 25 at 1:55 PM

$ALZN

0 · Reply

anachartanalyst Sep. 25 at 1:01 PM

$ALZN https://anachart.com/wp-content/uploads/ana_temp/1758805295_soc-img.jpg

0 · Reply

hiwatt Sep. 23 at 11:55 PM

$ALZN Another sell by Todd Ault, This makes 13 in the last 6 months. I guess this is what you do when your other company (Gpus) fall s 83% in the last 6 months. I'm trying to wrap my head around his end game here. It appears he is selling big blocks of Alzn, giving the appearance of insider selling, while at the same time buying small blocks of Gpus, giving the appearance of insider buying. Anyway, his strategy isn't working because Gpus keeps falling and while Alzn has fallen in the last 6 months, it has held steady for the past 6 weeks, even though Mr Ault continues to sell.

0 · Reply

hiwatt Sep. 23 at 11:03 AM

$ALZN Would not be surprised to see results from Harvard trials come in sooner than expected, based on what they have already updated. We know first subject met criteria in early April, began dosing in early May. We know last subject met criteria in late June and should've started dosing by August. The study takes basically 42 days to complete, 14 days dosing, 14 day washout, 14 day reverse dosing. That would mean last subject finished by mid September and results are to be post one month after trial completion. That could mean the numbers may get post by mid October or first of November. Hopefully we get some movement in stock price over the next 6 weeks from people getting back in the game. Remember, this stocked IPO was $1.15B and we're sitting at $7.4M.

0 · Reply

hiwatt Sep. 22 at 11:53 AM

$ALZN I guess this headline may have been what spooked the rally that started last week. But when you dive deeper into this transaction, it speaks more about Mr Milton that about Alzn. Mr Milton, which I admire, is an investment activist and the founder of Alzn. He also has another company, Hyperscale Data (Gpus) which is down 100% in the last 3 years and down from $4 a share in June to just .52 cents, despite 6 reverse stock splits in the last 3 years. The day before he sold 22k shares of Alzn, he received a 100k shares and still owns close to 90K shares thru his holdings He went and bought UUU on the same day, I assume for a quicker profit, given the the fact Gpus is underperforming.------- Ault Milton C III sells Alzamend Neuro (ALZN) stock for $56,696 Insider Trading Published 09/19/2025

1 · Reply

Market Cap	7.94M
Revenue (ttm)	0.00
Net Income (ttm)	-4.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	359,300
Avg Vol	126,890
Day's Range	N/A - N/A
Shares Out	3.14M
Stochastic %K	83%
Beta	-0.27
Analysts	Sell
Price Target	$42.00